-

02:38:05 PM

OMER Stock News

OMER - Omeros Corporation

09/15/22 9:06 AM

Nasdaq : OMER

covid-19

Omeros Corporation Reports Narsoplimab Treatment Results in Critically Ill COVID-19 Patients in I-SPY COVID Trial

Omeros Corporation today reported results from the narsoplimab arm of the I-SPY COVID Trial, sponsored by Quantum Leap Healthcare Collaborative. Analysis in the randomized patient population shows that the addition of narsoplimab to treatment of critically ill patients with COVID-19 reduces the mortality risk (hazard ratio[ HR]= 0.81, with probability[ HR.

RHEA-AI

neutral

09/15/22 9:02 AM

Nasdaq : OMER

covid-19

I-SPY COVID Trial Sponsored by Quantum Leap Healthcare Collaborative Reports Assessment of Narsoplimab for Treatment of Critically Ill Patients With COVID-19

Quantum Leap Healthcare Collaborative, sponsor of the I-SPY COVID Trial, and Omeros Corporation, developer of the investigational agent narsoplimab, announced that enrollment has been closed and data have been analyzed in the narsoplimab arm of the I-SPY COVID Trial. The analysis in the randomized patient population, including those...

RHEA-AI

negative

08/17/22 8:40 AM

Nasdaq : OMER

Omeros Corporation Receives Interim Response from FDA on Formal Dispute Resolution Request for Narsoplimab

Omeros Corporation today announced that the United States Food and Drug Administration provided an interim response to the company' s formal dispute resolution request submitted to the Agency in June, appealing the earlier decision by the FDA review division to issue a complete response letter for the biologics license application for narsoplimab in the...

RHEA-AI

neutral

08/09/22 4:02 PM

Nasdaq : OMER

earnings

Omeros Corporation Reports Second Quarter 2022 Financial Results

Omeros Corporation, a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation and immunologic diseases, including complement-mediated diseases and cancers, today announced recent...

RHEA-AI

neutral

08/04/22 8:30 AM

Nasdaq : OMER

earnings

Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2022

Omeros Corporation, today announced that the company will issue its second quarter financial results for the period ended June 30, 2022, on Tuesday, August 9, 2022, after the market closes. To access the live conference call via phone, please dial 634-2592 from the United States and Canada or 902-4100 internationally and ask to be placed into the Omeros earnings...

RHEA-AI

neutral

07/29/22 8:45 AM

Nasdaq : OMER

FDA Grants Orphan Drug Designation to Omeros' MASP-3 Inhibitor OMS906 for Treatment of Paroxysmal Nocturnal Hemoglobinuria

Omeros Corporation today announced that OMS906 has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of paroxysmal nocturnal hemoglobinuria. "We are excited to begin clinical studies to demonstrate the efficacy of OMS906 in alternative pathway-related disorders," said Gregory A. Demopulos, M.D., chairman and...

RHEA-AI

positive

06/15/22 8:00 AM

Nasdaq : OMER

Omeros Announces Webcast Details for Annual Meeting of Shareholders

Omeros Corporation, today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually, on Friday, June 17, 2022, starting at 10:00 a.m. Pacific Time. The live webcast of the Annual Meeting of Shareholders can be accessed through www.virtualshareholdermeeting.com/OMER2022. As described in the...

RHEA-AI

neutral

05/10/22 4:02 PM

Nasdaq : OMER

earnings

Omeros Corporation Reports First Quarter 2022 Financial Results

Omeros Corporation, a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation and immunologic diseases, including complement-mediated diseases and cancers, today announced recent...

RHEA-AI

neutral

05/04/22 8:30 AM

Nasdaq : OMER

earnings

Omeros Corporation to Announce First Quarter Financial Results on May 10, 2022

Omeros Corporation, today announced that the company will issue its first quarter financial results for the period ended March 31, 2022, on Tuesday, May 10, 2022, after the market closes. To access the live conference call via phone, please dial 831-4029 from the United States and Canada or 663-6278 internationally. A telephone replay will be available for one...

RHEA-AI

neutral

04/20/22 8:45 AM

Nasdaq : OMER

Omeros Announces Journal of Clinical Oncology Publication Detailing Pivotal Trial Results for Narsoplimab in HSCT-TMA

Omeros Corporation today announced the online publication of a manuscript detailing the results of its pivotal study assessing efficacy and safety of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy, an often-lethal complication of stem-cell transplantation for which there is no approved...

RHEA-AI

neutral

OMER Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.omeros.com
CeoGregory Demopulos
Security nameOmeros Corporation
Issue typecs
SectorManufacturing
Sic code2834
Employees277
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address201 Elliott Ave W
StateWashington
CitySeattle
Zip98119-4240
CountryUS
Phone12066765000

About Omeros Corporation

Omeros is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. Its commercial product OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3% continues to gain market share in cataract surgery. Omeros' lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application under priority review by FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome and COVID-19. OMS906, Omeros' inhibitor of MASP-3, the key activator of the alternative pathway of complement, is in a Phase 1 clinical trial, and the company's PDE7 inhibitor program OMS527, targeting addiction and movement disorders, has successfully completed a Phase 1 trial. Omeros' pipeline holds a diverse group of preclinical programs including a proprietary-asset-enabled antibody-generating technology and a proprietary GPCR platform through which it controls 54 GPCR drug targets and their corresponding compounds. One of these novel targets, GPR174, modulates a new cancer immunity axis recently discovered by Omeros, and the company is advancing GPR174-targeting antibodies and small-molecule inhibitors.